
Novartis AG
NVSHealthcare|Drug Manufacturers - General|Switzerland
$152.84
+0.00 (+0.00%)
DCF (FCF)
$89.99
Earnings Power
$56.11
Upcoming Data Readouts (38)
Jun 2026
Est. completion
P1Acute Lymphoblastic Leukemia
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882n=12
Jul 2026
Est. completion
P1Multiple Myeloma
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257n=30
Aug 2026
Est. completion
P4Ankylosing Spondylitis (AS)
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
NCT05303285n=100
Sep 2026
Est. completion
Metastatic Non-small Cell Lung Cancer (NSCLC)
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
NCT02622581n=12,400
Sep 2026
Est. completion
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
NCT06785675n=48
Oct 2026
Est. completion
Primary Hypercholesterolemia
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992n=847
Oct 2026
Est. completion
Oct 2026
Est. completion
Non-Small-Cell Lung Carcinoma
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
NCT05703516n=250
Nov 2026
Est. completion
P4Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
NCT06427811n=85
Dec 2026
Est. completion
Dec 2026
Est. completion
P1Breast Cancer
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579n=48
Jan 2027
Est. completion
P3Breast Cancer
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735n=234
Feb 2027
Est. completion
P2Melanoma
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621n=134
Feb 2027
Est. completion
P3Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
NCT06868212n=400
Feb 2027
Est. completion
P2Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04524000n=24
Feb 2027
Est. completion
P1Mycosis Fungoides
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05944562n=24
Mar 2027
Est. completion
P3B-cell Acute Lymphoblastic Leukemia
Study of Out of Specification for Tisagenlecleucel
NCT04094311n=200
Apr 2027
Est. completion
P1ALK-positive NSCLC
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
NCT02393625n=57
Apr 2027
Est. completion
Paroxysmal Nocturnal Hemoglobinuria
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691n=80
Jul 2027
Est. completion
P3Ovarian Neoplasm Epithelial
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978n=540
Awaiting Results (15)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P3
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
NCT06267560Mar 2026
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
NCT07465679Mar 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749Oct 2025
P1P2
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
NCT03945318Jul 2025
P4
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
NCT06498050Sep 2024
P2
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01990196Jul 2023
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT04497285